BEOVU is a prescription medicine. BEOVU used for Neovascular (Wet) Age-Related Macular Degeneration (AMD).
INDICATIONS AND USAGE
BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD)
DOSAGE FORMS & STRENGTHS
Intravitreal injection: 6 mg/0.05 mL solution in a single-dose vial
Manufactured By: Novartis Pharmaceuticals Corporation
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “BEOVU ® (brolucizumab-dbll) injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Brolucizumab, sold under the trade name Beovu, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.